Omeros (NASDAQ:OMER) Upgraded at StockNews.com

Omeros (NASDAQ:OMER) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Several other research analysts also recently weighed in on OMER. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Thursday, November 14th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Price Performance

Shares of OMER stock opened at $6.03 on Wednesday. Omeros has a 1 year low of $1.60 and a 1 year high of $7.51. The firm has a fifty day moving average price of $4.19 and a 200-day moving average price of $4.13. The company has a market cap of $349.44 million, a price-to-earnings ratio of -2.61 and a beta of 1.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MML Investors Services LLC boosted its holdings in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after acquiring an additional 3,839 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,000 shares during the last quarter. Comerica Bank lifted its holdings in shares of Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.